Cargando…

Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

BACKGROUND: Chronic stable angina (CSA) is a cardiovascular disease with high prevalence. At present, drug treatment is still the main measure of stable angina pectoris. Traditional Chinese medicine has a long history in the treatment of CSA. Qi stagnation and Blood stasis syndrome is a common syndr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jun-Nan, Zhang, Ying, Lan, Xu, Chen, Yao, Li, Jing, Zhang, Ping, Wu, Li-Qi, Jia, Shu-Ting, Liu, Yue, Xu, Feng-Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709279/
https://www.ncbi.nlm.nih.gov/pubmed/31374015
http://dx.doi.org/10.1097/MD.0000000000016539
_version_ 1783446173611196416
author Zhao, Jun-Nan
Zhang, Ying
Lan, Xu
Chen, Yao
Li, Jing
Zhang, Ping
Wu, Li-Qi
Jia, Shu-Ting
Liu, Yue
Xu, Feng-Qin
author_facet Zhao, Jun-Nan
Zhang, Ying
Lan, Xu
Chen, Yao
Li, Jing
Zhang, Ping
Wu, Li-Qi
Jia, Shu-Ting
Liu, Yue
Xu, Feng-Qin
author_sort Zhao, Jun-Nan
collection PubMed
description BACKGROUND: Chronic stable angina (CSA) is a cardiovascular disease with high prevalence. At present, drug treatment is still the main measure of stable angina pectoris. Traditional Chinese medicine has a long history in the treatment of CSA. Qi stagnation and Blood stasis syndrome is a common syndrome of CSA. Xinnaoning (XNN) capsule is considered as an effective adjuvant treatment for CSA with the efficacy of promoting qi and blood circulation but lack of high-quality clinical evidence. The purpose of this study is to evaluate the efficacy and safety of XNN capsule compared with placebo by clinical trial. METHODS: This multicenter, randomized, double-blind, placebo-controlled trial will be conducted with a total of 240 participants diagnosed with chronic stable angina (qi stagnation and blood stasis syndrome). The participants will be randomized (1:1) into groups receiving either XNN or placebo for 12 weeks. After a 2-week run-in period, they will receive either XNN or placebo (3 pills, 3 times daily) for 12 weeks on the basis of conventional therapy. The primary outcomes include changes in the integral scores of angina symptoms. The secondary outcome measures include changes in the total score of traditional Chinese medicine syndrome, severity grading of angina pectoris, the number of angina pectoris per week, nitroglycerin dosage, score of seattle angina scale, serum homocysteine, incidence of cardiovascular events. Safety outcomes will also be assessed. Adverse events will be monitored throughout the trial. RESULTS: This study will investigate whether XNN capsule can alleviate clinical symptoms, and improve quality of life of patients with chronic stable angina (qi stagnation and blood stasis syndrome). The results of this study will provide clinical evidence for the application of XNN capsule in the treatment of chronic stable angina. TRIAL REGISTRATION: ClinicalTrials.gov: NCT 03914131.
format Online
Article
Text
id pubmed-6709279
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67092792019-10-01 Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial Zhao, Jun-Nan Zhang, Ying Lan, Xu Chen, Yao Li, Jing Zhang, Ping Wu, Li-Qi Jia, Shu-Ting Liu, Yue Xu, Feng-Qin Medicine (Baltimore) Research Article BACKGROUND: Chronic stable angina (CSA) is a cardiovascular disease with high prevalence. At present, drug treatment is still the main measure of stable angina pectoris. Traditional Chinese medicine has a long history in the treatment of CSA. Qi stagnation and Blood stasis syndrome is a common syndrome of CSA. Xinnaoning (XNN) capsule is considered as an effective adjuvant treatment for CSA with the efficacy of promoting qi and blood circulation but lack of high-quality clinical evidence. The purpose of this study is to evaluate the efficacy and safety of XNN capsule compared with placebo by clinical trial. METHODS: This multicenter, randomized, double-blind, placebo-controlled trial will be conducted with a total of 240 participants diagnosed with chronic stable angina (qi stagnation and blood stasis syndrome). The participants will be randomized (1:1) into groups receiving either XNN or placebo for 12 weeks. After a 2-week run-in period, they will receive either XNN or placebo (3 pills, 3 times daily) for 12 weeks on the basis of conventional therapy. The primary outcomes include changes in the integral scores of angina symptoms. The secondary outcome measures include changes in the total score of traditional Chinese medicine syndrome, severity grading of angina pectoris, the number of angina pectoris per week, nitroglycerin dosage, score of seattle angina scale, serum homocysteine, incidence of cardiovascular events. Safety outcomes will also be assessed. Adverse events will be monitored throughout the trial. RESULTS: This study will investigate whether XNN capsule can alleviate clinical symptoms, and improve quality of life of patients with chronic stable angina (qi stagnation and blood stasis syndrome). The results of this study will provide clinical evidence for the application of XNN capsule in the treatment of chronic stable angina. TRIAL REGISTRATION: ClinicalTrials.gov: NCT 03914131. Wolters Kluwer Health 2019-08-02 /pmc/articles/PMC6709279/ /pubmed/31374015 http://dx.doi.org/10.1097/MD.0000000000016539 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Zhao, Jun-Nan
Zhang, Ying
Lan, Xu
Chen, Yao
Li, Jing
Zhang, Ping
Wu, Li-Qi
Jia, Shu-Ting
Liu, Yue
Xu, Feng-Qin
Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title_full Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title_fullStr Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title_full_unstemmed Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title_short Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title_sort efficacy and safety of xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709279/
https://www.ncbi.nlm.nih.gov/pubmed/31374015
http://dx.doi.org/10.1097/MD.0000000000016539
work_keys_str_mv AT zhaojunnan efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT zhangying efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT lanxu efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT chenyao efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT lijing efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT zhangping efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT wuliqi efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT jiashuting efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT liuyue efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT xufengqin efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial